Hookipa Pharma Announced Additional Preliminary Phase 2 Data On HB-200 In Combination with Pembrolizumab; 42% Objective Response Rate Among 19 Evaluable Patients With With HPV16+ Head And Neck Cancers
Portfolio Pulse from Charles Gross
Hookipa Pharma Inc. (NASDAQ:HOOK) has announced preliminary data from its ongoing Phase 2 trial of HB-200 in combination with pembrolizumab in patients with HPV16+ head and neck cancer. The data showed a 42% objective response rate and a disease control rate of 74% across 19 patients, doubling the response rate for pembrolizumab alone. The company plans to start a randomized trial of HB-200 in combination with pembrolizumab as a 1st-line treatment in 2024.
October 22, 2023 | 2:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Hookipa Pharma's preliminary Phase 2 data shows promising results for its HB-200 treatment in combination with pembrolizumab. This could potentially boost the company's stock in the short term.
The positive preliminary data from the Phase 2 trial of HB-200 in combination with pembrolizumab indicates a potential breakthrough in the treatment of HPV16+ head and neck cancer. This could lead to increased investor confidence in Hookipa Pharma, potentially driving up the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100